Technology Appraisal Committee Meeting (Committee [A])

Minutes: Confirmed

Date and Time: 16th August 2016, 10am – 5pm

Venue: NICE London Offices
       Prince of Wales Suite
       10 Spring Garden
       SW1A 2BU

Present:
1. Chair Dr Jane Adam Present for all notes
2. Professor John Watkins Present for all notes
3. Dr Graham Ash Present for all notes
4. Dr Ian Bernstein Present for all notes
5. Mr Adrian Griffin Present for notes 1 to 16
6. Dr Rachel Hobson Present for all notes
7. Professor John McMurray Present for all notes
8. Dr Mohit Misra Present for all notes
9. Ms Pamela Rees Present for all notes
10. Dr Paul Robinson Present for notes 1 to 16
11. Ms Ellen Rule Present for all notes
12. Mr Stephen Sharpe Present for all notes
13. Dr Brian Shine Present for all notes
14. Mr David Thomson Present for all notes
15. Professor Olivia Wu Present for all notes
16. Dr Nerys Woolacott Present for all notes
17. Rita Faria Present for all notes

In attendance:

Janet Robertson Associate Director, National Institute for Health and Care Excellence Present for all notes

Liv Gualda Project Manager, National Institute for Health and Care Excellence Present for all notes

Marcia Miller Technology Administrator, National Institute for Health and Care Excellence Present for all notes

Helen Tucker Technical Analyst, National Institute for Health and Care Present for notes 1 to 16
Excellence

Eleanor Donegan  Technical Adviser, National Institute for Health and Clinical Excellence  Present for notes 1 to 16

Carl Prescott  Technical Analyst, National Institute for Health and Care Excellence  Present for notes 17 to 28

Joanna Richardson  Technical Adviser, National Institute for Health and Clinical Excellence  Present for notes 17 to 28

Evidence review group

Rachid Rafia  School of Health Related Research  Present for notes 1 to 13

Sarah Davis  School of Health Related Research  Present for notes 1 to 13

Abdullah Pandor  School of Health Related Research  Present for notes 1 to 13

Norman Waugh  University of warwick  Present for notes 1 to 13

Ewen Cummings  University of Warwick  Present for notes 1 to 13

Clinical Experts

Dr Andrew Mcmillan CONSULTANT HAEMATOLOGIST nominated by Royal College of Physicians  Present for notes 1 to 13

Dr John Gribben  Professor of Medical Oncology, nominated by Roche  Present for notes 1 to 13

Dr Roger Gadsby  Honorary Associate Clinical Professor nominated by Janssen  Present for notes 16 to 25

Dr Michael Feher  CONSULTANT IN CLINICAL PHARMACOLOGY & DIABETES  Present for notes 16 to 25

Patients Experts

Katharine Robinson  Patient expert nominated by Lymphoma Association  Present for notes 1 to 13

Ruth Waxman  Patient expert nominated by Diabetes UK  Present for notes 16 to 25
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma [ID841]

2. The Chair informed the Committee of the non-public observers at this meeting: Chloe Kastoryano and Ria Skelton.

3. Apologies were received from Dr Jeremy Braybrooke, Dr Justin Daniels, Dr Andrew England, Dr Anne McCune, Mrs Sarah Parry and Professor Iain Squire

Notes from the last meeting

4. Minutes of the last meeting were agreed

Appraisal of Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma [ID841]

Part 1 – Open session

5. The Chair welcomed the invited experts: Dr John Gribben, Dr Andrew McMillan, Katharine Robinson o the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Roche to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Jane Adam, Professor John Watkins, Dr Graham Ash, Dr Ian Bernstein, Mr Adrian Griffin, Dr Rachel Hobson, Professor John McMurray Dr Mohit Misra, Ms Pamela Rees, Dr Paul Robinson, Ms Ellen Rule, Mr Stephen Sharp, Dr Brian Shine, Mr David Thomson, Professor Olivia Wu, Dr Nerys Woolacott and Rita Faria all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma

8. The Chair asked all NICE Staff to declare any relevant interests.

All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma
9. The Chair asked all other invited guests ERG and invited experts, not including observers) to declare their relevant interests.

Rachid Rafia, Sarah Davis, Abdullah Pandor and Katharine Robinson all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma.

9.1. Dr John Gribben declared a personal non-specific financial interest as he has received honoraria for advisory boards and speaking for Roche, he has no personal financial interest to declare.
9.1.1. It was agreed that this declaration would not prevent Dr John Gribben from participating in this section of the meeting.

9.2. Dr Andrew McMillan declared a personal non-specific financial interest as he has received honoraria from Roche and NAPP for Advisory boards, speaking at Satellite symposia and received sponsorship to attend International meetings.
9.2.1. It was agreed that this declaration would not prevent Dr Andrew McMillan from participating in this section of the meeting.

10. The Chair introduced the lead team, Professor John Watkin, Mr David Thomson and Dr Mohit Misra who gave presentations on the clinical effectiveness and cost effectiveness of Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma
16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
Appraisal of Dapagliflozin in triple therapy regimens for treating type 2 diabetes

Part 1 – Open session

17. The Chair welcomed the invited experts: Ewen Cummings, Dr Roger Gadsby, Dr Michael Feher, Norman Waugh and Ruth Waxman to the meeting and they introduced themselves to the Committee.

18. The Chair welcomed company representatives from Roche to the meeting.

19. The Chair asked all Committee members to declare any relevant interests

19.1. Dr Jane Adam, Dr John Watkins, Dr Graham Ash, Dr Ian Bernstein Professor John McMurray, Dr Mohit Misra, Ms Pamela Rees, Dr Paul Robinson, Ms Ellen Rule, Mr Stephen Sharpe, Dr Brian Shine, Mr David Thomson, Professor Olivia Wu, Dr Nerys Woolacott and Rita Faria all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Appraisal of Dapagliflozin in triple therapy regimens for treating type 2 diabetes.

19.2. Dr Rachel Hobson declared a non-personal specific financial interest as she participated in 2 advisory boards for Janssen in March and June 2015 about canagliflozin.

19.2.1 It was agreed that this declaration would not prevent Dr Rachel Hobson from participating in this section of the meeting.

19.3. Mr Adrian Griffin was absent as Janssen the comparator company for the appraisal is owned by his employer Johnson and Johnson.

19.4. Dr Paul Robinson was absent as the comparator drug staglitin is made by his employer Merck Sharpe and Dohme.

20. The Chair asked all NICE Staff to declare any relevant interests.

20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Appraisal of Dapagliflozin in triple therapy regimens for treating type 2 diabetes.

21. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
21.1. Ewen Cummings, Norman Waugh and Ruth Waxman all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of **Dapagliflozin in triple therapy regimens for treating type 2 diabetes**.

21.2. Dr Michael Feher declared a personal non-specific financial interest as he has sat on Advisory boards for Novo Nordisk, Sanofi, MSD and Eli Lilly

21.2.1. It was agreed that this declaration would not prevent Dr Michael Feher from participating in this section of the meeting

21.3. Dr Roger Gadsby declared a personal non specific financial interest as he has received payment for advisory work from Janssen and Eli Lilly in the past 2 years

21.3.1. It was agreed that this declaration would not prevent Dr Roger Gadsby from participating in this section of the meeting

22. The Chair introduced the lead team, Dr Mohit Misra, Pamela Rees and Mohit and Dr Oliva Wu who gave presentations on the clinical effectiveness and cost effectiveness of **Dapagliflozin in triple therapy regimens for treating type 2 diabetes**.

23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

26. Discussion on confidential information continued. This information was supplied by the company.

27. The Committee continued to discuss the clinical and cost effectiveness of **Dapagliflozin in triple therapy regimens for treating type 2 diabetes**.

28. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

29. Tuesday 20th September 2016 at 10am, Prospero House, 241 Borough High Street, SE1 IGB.